| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,098 | 0,118 | 07:34 | |
| 0,098 | 0,118 | 07:34 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BRII BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 03.07. | Brii Bio reports mixed results from hepatitis B studies | 3 | Investing.com | ||
| 03.07. | Brii Biosciences Limited: Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B | 75 | PR Newswire | End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses... ► Artikel lesen | |
| 03.07. | BRII-B (02137): INSIDE INFORMATION ANNOUNCES TOPLINE END-OF-TREATMENT DATA FROM PHASE 2B ENRICH AND ENHANCE STUDIES FOR THE TREATMENT OF CHRONIC HEPATITIS ... | 1 | HKEx | ||
| 17.06. | BRII-B (02137): VOLUNTARY ANNOUNCEMENT SHARE BUY-BACK PROGRAMME | - | HKEx | ||
| 16.06. | BRII-B (02137): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 16, 2026 | - | HKEx | ||
| 22.05. | BRII-B (02137): INSIDE INFORMATION IN RELATION TO ARBITRATION PROCEEDINGS | 3 | HKEx | ||
| 23.04. | BRII-B (02137): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 23.04. | BRII-B (02137): NOTIFICATION LETTER AND CHANGE REQUEST FORM FOR REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| 23.04. | BRII-B (02137): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx | ||
| 23.04. | BRII-B (02137): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | BRII-B (02137): (1) PROPOSALS FOR ADOPTION OF THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS; (2) RE-ELECTION OF RETIRING DIRECTORS; (3) RE-APPOINTMENT ... | - | HKEx | ||
| 23.04. | BRII-B (02137): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | BRII-B (02137): 2025 ANNUAL REPORT | - | HKEx | ||
| 16.04. | BRII-B (02137): INSIDE INFORMATION IN RELATION TO ARBITRATION PROCEEDINGS | 2 | HKEx | ||
| 19.03. | Brii Biosciences Limited: Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results | 590 | PR Newswire | Advancing HBV Functional Cure Toward Key Phase 2b Data Readouts
Increasing Discovery Efforts to Drive Long-term Value Creation
Strong Cash Position Supporting Strategic... ► Artikel lesen | |
| 19.03. | BRII-B (02137): NOTIFICATION OF 2025 PFIC STATUS | - | HKEx | ||
| 19.03. | BRII-B (02137): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx | ||
| 09.03. | BRII-B (02137): DATE OF BOARD MEETING | 1 | HKEx | ||
| 21.08.25 | Brii Biosciences Limited: Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results | 231 | PR Newswire | Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy
Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOGEN | 177,54 | +0,60 % | BofA senkt Kursziel für Biogen wegen gestiegener Erwartungen | ||
| ILLUMINA | 172,78 | -0,16 % | Element Biosciences, Inc.: Element Biosciences gewinnt deutschen Patentstreit gegen Illumina | Das Landgericht München I stellt fest, dass Illumina die geistigen Eigentumsrechte von Element im Bereich der Sequenzierung verletzt, verbietet den Vertrieb von Illumina-Systemen und zugehörigen... ► Artikel lesen | |
| NANOREPRO | 2,130 | -0,47 % | EQS-News: NanoRepro AG: Strategischer Reviewprozess zeigt erste Ergebnisse - Plattform-Struktur nimmt Form an | EQS-News: NanoRepro AG
/ Schlagwort(e): Strategische Unternehmensentscheidung/Unternehmensrestrukturierung
NanoRepro AG: Strategischer Reviewprozess zeigt erste Ergebnisse - Plattform-Struktur... ► Artikel lesen | |
| CYTODYN | 0,180 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| IMMUNIC | 12,935 | +3,11 % | EQS-News: Immunic AG: Immunic to Participate in Investor Conferences in July | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor Conferences in July
09.07.2026 / 12:30 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 19,460 | -0,79 % | CSE Bulletin: Consolidation - Adaptogenics Health Corp. (ADPT) | Le 13 juillet/July 2026
Adaptogenics Health Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated share for four (4) pre-consolidated... ► Artikel lesen | |
| GENPREX | 7,430 | -0,80 % | XFRA 2DE1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILGENPREX INC. O.N.... ► Artikel lesen | |
| PERSONALIS | 10,920 | +1,72 % | Paukenschlag: AKTIONÄR-Tipp Personalis im Übernahme-Visier? | Spekulationen um eine mögliche Übernahme haben die Aktie von Personalis gegen Ende der vergangenen Handelswoche angetrieben. Laut einem Medienbericht soll es mehrere mögliche Kaufinteressenten für den... ► Artikel lesen | |
| VITROLIFE | 7,765 | +0,58 % | Vitrolife AB: Interim report Q2, 2026: Strong margins and high profitability in soft market conditions | Second quarterSales of SEK 857 (871) million, a decrease of 1% in local currencies and 2% decrease in SEK. Organic growth in local currencies excluding exited business of the NACE and GDPX product lines... ► Artikel lesen | |
| PLURI | 4,660 | -100,00 % | Pluri Inc.: Pluri Chairman Alejandro Weinstein's Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30% | HAIFA, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today provided... ► Artikel lesen | |
| LEGEND BIOTECH | 20,800 | 0,00 % | Why Legend Biotech stock fell 10% despite record Carvykti sales | ||
| ENVERIC BIOSCIENCES | 1,300 | -1,52 % | Morning Market Movers: Huachen AI Parking, FatPipe, Enveric Biosciences, Akanda See Big Swings | TEL AVIV (dpa-AFX) - At 8:00 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ENANTA | 11,300 | -0,88 % | Enanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus | MAVIRET (Glecaprevir/Pibrentasvir) is the Only Treatment Approved in the European Union for Both Acute and Chronic Hepatitis C Virus (HCV) Infection Approval Allows Providers to Treat HCV... ► Artikel lesen | |
| NATURAL ALTERNATIVES INTERNATIONAL | 1,990 | +1,53 % | Natural Alternatives International Inc: Natural Alternatives International, Inc. Announces 2026 Q3 and YTD Results | CARLSBAD, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements... ► Artikel lesen | |
| MONOPAR THERAPEUTICS | 100,20 | +7,97 % | Monopar Therapeutics Inc.: Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease | WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments... ► Artikel lesen |